The top 10 drugs, in terms of advertising spending, account for 75% of all the money spent on advertising in the pharmaceutical industry. 24/7 Wall St. has included the big movers, along with information on the companies, including the consensus price target and 52-week range.
Eli Lilly & Co. (NYSE: LLY) took the top spot in 2014 with its drug Cialis, which treats erectile dysfunction. A total of $272 million was spent on advertising for Cialis, according to Kantar Media. Shares of Eli Lilly were up 0.7% at $85.41 on Friday. The stock has a consensus analyst price target of $84.06 and a 52-week trading range of $60.14 to $87.24.
ALSO READ: Are Cancer Drugs Becoming Too Costly for Their Effectiveness?
Pfizer Inc. (NYSE: PFE) took two spots in the top five, with Lyrica and Viagra. Lyrica treats nerve and muscle pain caused by diabetes, along with shingles, fibromyalgia or a spinal injury. Viagra is another erectile dysfunction drug. Pfizer shares were relatively flat at $34.06 on Friday. The stock has a consensus price target of $37.94 and a 52-week range of $27.51 to $35.53.
AbbVie Inc. (NYSE: ABBV) was previously the top advertising spender in 2013, when Humira topped the list. And Humira is still in the top five. The drug treats arthritis, ankylosing spondylitis, Crohn’s disease or similar problems. Shares of AbbVie were up 0.9% at $70.47 on Friday. The consensus analyst price target is $74.00, and the 52-week range is $51.37 to $70.76.
Bristol-Meyers Squibb Co. (NYSE: BMY) rounds out the top five with Eliquis. This drug is part of the next generation of blood thinners. Shares were up 1.1% to $67.56 on Friday, within a 52-week trading range of $47.34 to $69.86. The stock’s consensus price target is $70.33.
According to Kantar Media, the top five ranked as such:
- Cialis $272 million
- Humira $259 million
- Lyrica $246 million
- Viagra $232 million
- Eliquis $221 million
ALSO READ: 4 Health Care Stocks That Are Very Likely Buyout Targets
Top Gaining Stocks
Top Losing Stocks